The deal – announced in a Bombay Stock Exchange (BSE) filing – is focused on the registration and commercialization of three Dr Reddy’s biosimilar products in Turkey.
TR-Pharma will register the drugs – details of which have not been released – and will also produce the active pharmaceutical ingredients (APIs) for the three products.
The agreement will also see Dr Reddy’s transfer manufacturing technology and processes to Istanbul-headquartered TR-Pharm.
TR-Pharm general manager Mehmet Goker said: “Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports.”
Dr Reddy’s portfolio of biosimilar products includes versions of Aranesp (darbopoetin alfa), Neupogen (filgrastim) and Neulasta (pegfilgrastrim) and MabThera (rituximab).
Neither firm responded to a request for comment.
Biosimilars in Turkey
Russia’s CJSC Biocad agreed to supply Turkey’s Kocak Farma with the API for rituximab in a five-year supply and commercialisation deal signed in 2013.
In 2015, Turgut Ilaç announced gained access to biosimilar manufacturing technology in an agreement with Merck Millipore. The deal also saw the latter provide Turgut with facility design services and process development support.
At the time Turgut Ilaç said the initial focus of the manufacturing collaboration will be biosimilars for the treatment of non-small cell lung carcinoma and rheumatoid arthritis.